This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ritland, S. R. Articles by Gendler, S. J. Search for Related Content PubMed PubMed Citation Articles by Ritland, S. R. Articles by Gendler, S. J.

Evaluation of 5-Aminosalicylic Acid (5-ASA) for Cancer Chemoprevention: Lack of Efficacy against Nascent Adenomatous Polyps in the Apc^Min Mouse¹

Departments of Biochemistry and Molecular Biology [S. R. R., S. J. G.], Gastroenterology [J. A. L.], and Biostatistics [A. L. W.], Mayo Clinic Scottsdale, Scottsdale, Arizona 85259; Departments of Medicine (Division of Hematology) and Anatomy and Structural Biology, Albert Einstein College of Medicine, Bronx, New York 10461 [R. E. H.]; and Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232 [J. D. M.]

Recent experimental and epidemiological evidence suggests that nonsteroidal anti-inflammatory drugs (NSAIDs) are effective in the prevention of colorectal cancer. However, the toxicity associated with the long-term use of most classical NSAIDs has limited their usefulness for the purpose of cancer chemoprevention. Inflammatory bowel disease (IBD) patients, in particular, are sensitive to the adverse side effects of NSAIDs, and these patients also have an increased risk for the development of intestinal cancer. 5-Aminosalicylic acid (5-ASA) is an anti-inflammatory drug commonly used in the treatment of IBD and may provide protection against the development of colorectal cancer in these patients. To directly evaluate the ability of 5-ASA to suppress intestinal tumors, we studied several formulations of 5-ASA (free acid, sulfasalazine, and Pentasa) at multiple oral dosage levels [500, 2400, 4800, and 9600 parts/million (ppm)] in the adenomatous polyposis coli (Apc) mouse model of multiple intestinal neoplasia (Min). Although the Apc^Min mouse is not a model of colitis-associated neoplasia, it is, nonetheless, a useful model for assessing the ability of anti-inflammatory agents to prevent tumor formation in a genetically preinitiated population of cells. We used a study design in which drug was provided ad libitum through the diet beginning at the time of weaning (28 days of age) until 100 days of age. We included 200 ppm of piroxicam and 160 ppm of sulindac as positive controls, and the negative control was AIN-93G diet alone. Treatment with either piroxicam or sulindac produced statistically significant reductions in intestinal tumor multiplicity (95% and 83% reductions in tumor number, respectively; P < 0.001 versus controls). By contrast, none of the 5-ASA drug formulations or dosage levels produced consistent dose-progressive changes in polyp number, distribution, or size, despite high luminal and serum concentrations of 5-ASA and its primary metabolite N-acetyl-5-ASA. Thus, 5-ASA does not seem to possess direct chemosuppressive activity against the development of nascent intestinal adenomas in the Apc^Min mouse. However, because intestinal tumor development in the Apc^Min mouse is driven by a germline mutation in the Apc gene rather than by chronic inflammation, we caution that these findings do not definitively exclude the possibility that 5-ASA may exert a chemopreventive effect in human IBD patients.

This article has been cited by other articles:

				C. L. Bos, S. H. Diks, J. C.H. Hardwick, K. V. Walburg, M. P. Peppelenbosch, and D. J. Richel Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/{beta}-catenin pathway activity Carcinogenesis, December 1, 2006; 27(12): 2371 - 2382. [Abstract] [Full Text] [PDF]

				S. H. Itzkowitz and X. Yio Inflammation and Cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation Am J Physiol Gastrointest Liver Physiol, July 1, 2004; 287(1): G7 - G17. [Abstract] [Full Text] [PDF]

				D. E. Corpet and F. Pierre Point: From Animal Models to Prevention of Colon Cancer. Systematic Review of Chemoprevention in Min Mice and Choice of the Model System Cancer Epidemiol. Biomarkers Prev., May 1, 2003; 12(5): 391 - 400. [Abstract] [Full Text] [PDF]

				A. Reinacher-Schick, A. Schoeneck, U. Graeven, I. Schwarte-Waldhoff, and W. Schmiegel Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells Carcinogenesis, March 1, 2003; 24(3): 443 - 451. [Abstract] [Full Text] [PDF]

				G. A. Orner, W.-M. Dashwood, C. A. Blum, G. D. Diaz, Q. Li, and R. H. Dashwood Suppression of tumorigenesis in the Apcmin mouse: down-regulation of {beta}-catenin signaling by a combination of tea plus sulindac Carcinogenesis, February 1, 2003; 24(2): 263 - 267. [Abstract] [Full Text] [PDF]

				A. V. Tutter, C. J. Fryer, and K. A. Jones Chromatin-specific regulation of LEF-1-beta -catenin transcription activation and inhibition in vitro Genes & Dev., December 15, 2001; 15(24): 3342 - 3354. [Abstract] [Full Text] [PDF]